Navigation Links
Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
Date:1/23/2010

SINGAPORE, Jan. 23 /PRNewswire/ -- OrbusNeich announced that clinical data presented today at Asia PCR/Singapore LIVE 2010 demonstrated the benefits of the Genous Bio-engineered R stent in the treatment of two challenging patient subsets.

Specifically, presentations delivered by Prof. Robbert de Winter, M.D., Ph.D., of the Academic Medical Center (AMC) in Amsterdam and Wojciech Wojakowski, M.D., from Medical University of Silesia in Poland focused on the use of the Genous Bio-engineered R stent in patients with bifurcation lesions and patients with non ST-segment elevation acute coronary syndrome.

Prof. de Winter's presentation, titled "One Year Clinical Outcome after Provisional T Stenting with the Endothelial Progenitor Cell Capturing Stent for Bifurcation Lesions," featured a single-center study with 178 patients that compared the Genous Bio-engineered R stent to a previous bare metal stent control group of 465 patients at the AMC.  A 32 percent reduction of the composite of cardiac death, myocardial infarction or target lesion revascularization was reported between these two groups. The cumulative rate of definite or probable stent thrombosis was reduced by 57 percent in the Genous Bio-engineered R stent-treated group compared to the control group.

"Bifurcation lesions remain a challenge for interventional cardiologists," said Prof. de Winter. "The Genous Bio-engineered R stent, with a low rate of stent thrombosis, is an alternative for this challenging patient group."

Dr. Wojakowski presented data on the JACK-EPC trial, a comparison of the efficiency of high dose atorvastatin and endothelial progenitor-capture stents versus bare metal stents, in the reduction of neointimal formation in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). The randomized study with 60 patients compared the Genous Bio-engineered R stent with bare metal stents with concomitant high dose atorvastatin in the reduction of neointimal hyperplasia assessed by coronary angiography and IVUS after six months.

In the JACK-EPC trial, the Genous Bio-engineered R stent induced less neointimal hyperplasia and a lower binary restenosis rate of 13 percent in the Genous Bio-engineered R stent, compared to 26.6 percent in the control group. Importantly, the major adverse cardiac events (MACE) rate was reported at only 10 percent in the Genous Bio-engineered R stent treated patient group versus 16 percent in the bare metal stent treated group.

"In our small study, we observed a lower amount of neointimal proliferation with the EPC capture stent compared to the bare metal stent control," said Wojakowski.  "Good safety is indicated by comparable stent thrombosis.  We think this makes the Genous stent a very promising treatment strategy for ACS patients, especially those with high risk of bleeding or not eligible for prolonged dual antiplatelet therapy due to allergy to ASA or clopidogrel."

"Data from both presentations support the use of the Genous Bio-engineered R stent as an effective treatment option in what interventional cardiologists find to be challenging cases," said Al Novak, OrbusNeich's chairman and CEO. "We look forward to continuing to work with physicians to realize the full potential of the Genous technology."

About Genous  

Genous is OrbusNeich's patented endothelial progenitor cell (EPC) capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

OrbusNeich's Genous Bio-engineered R stent has been commercially available in over 60 countries since 2005.  The Genous stent has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies.  There is a growing body of evidence from multiple clinical studies that the Genous stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first pro-healing stent, the Genous Bio-engineered R stent, as well as stents, balloons and guiding catheters marketed under the names of Blazer™, R stent, Scoreflex™, SafeCut™, Sapphire™, Sapphire NC, Avita™, Avita HP and Lumina™. OrbusNeich is headquartered in Hong Kong and has operations in Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; Tokyo, Japan; and Shenzhen, China.  OrbusNeich, which has provided medical devices to physicians through its predecessor companies since 1979, supplies products today to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.    

SOURCE OrbusNeich

RELATED LINKS
http://www.OrbusNeich.com

'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams Pre-Clinical Development of Neuroprotective Parkinsons Therapies
2. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
3. ERT Demonstrates Patient Safety Expertise in Clinical Trials with New Knowledge Series of Papers
4. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
7. PharmaNet Development Group Symposia Crossing the Bridge from Preclinical to Clinical Studies to be Held February 2010 in Basel, Dusseldorf and Vienna
8. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. New Clinical Study Finds Masimo Perfusion Index (PI) Predicts Low Systemic Blood Flow in Preterm Infants
11. DATATRAKs eClinical(TM) 9.0 Software Release furthers Vision of DATATRAK ONE(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology:
(Date:6/27/2016)... , ... June 27, 2016 ... ... the patient payment industry today announced its strategic partnership with Connance, a ... workflows. , The two companies’ proven, proprietary technology combine to provide health ...
(Date:6/27/2016)... ... , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... Creek, Michigan (PRWEB) , ... June 26, 2016 , ... ... joined as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in ... in honor of the city’s history as home to some of the world’s leading ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/26/2016)... Clarkston, Michigan (PRWEB) , ... June 26, 2016 ... ... respect to fertility once they have been diagnosed with endometriosis. These women need ... but they also require a comprehensive approach that can help for preservation of ...
Breaking Medicine News(10 mins):